«Our findings contribute important new evidence about the natural history and survival of people affected
by synucleinopathies of various types.
Not exact matches
The population - based study
by Rodolfo Savica, M.D., Ph.D., and coauthors of the Mayo Clinic, Rochester Minn., included all the residents of Minnesota's Olmsted County and identified 461 patients with
synucleinopathies and 452 patients without for comparison.
A new article published
by JAMA Neurology compares survival rates among patients with
synucleinopathies, including Parkinson disease, dementia with Lewy bodies, Parkinson disease dementia and multiple system atrophy with parkinsonism, with individuals in the general population.
Yet if you look at people who develop the clinical syndrome of dementia, especially later in life, yes, they have amyloid in the brain but they also have other pathologic entities — vascular disease;
synucleinopathies [insoluble fibrils of the normally soluble protein, alpha - synuclein]; a tauopathy [which is marked
by disease - inducing, insoluble tangles of another protein, tau].
The clinical consortium is led
by AFFiRiS itself, and in addition to the PD booster trial, it is now recruiting for a separate Phase I trial of the α - synuclein vaccine against MSA, a
synucleinopathy differentiated from PD or LBD based on the cell populations affected, the regional concentration of AS neuropathology, and the spectrum of movement and other symptoms.